Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful ActivityValsamo Anagnostou, Patrick M. Forde, Mark Yarchoan et al.|Clinical Cancer Research|2017Cited by 181
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort studyRenée Schmitz, Marjanka K. Schmidt, Yi Ren et al.|BMJ|2023Cited by 44
DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCISEllen G. Engelhardt, Lotte Elshof, Renée Schmitz et al.|The Breast|2024Cited by 1
Abstract P1-22-02: Subsequent risk of ipsilateral breast events in a multinational DCIS cohort of 48.619 patients: A meta-analysis within the PRECISION consortiumRenée Schmitz, Marjanka K. Schmidt, Sandra W van den Belt-Dusebout et al.|Cancer Research|2022Cited by 0
Abstract 686: Subsequent invasive breast cancer risk after DCIS treatment in multinational PRECISION consortium cohorts comprising 48,576 patientsRenée Schmitz, Marjanka K. Schmidt, Alexandra W. van den Belt‐Dusebout et al.|Cancer Research|2022Cited by 0